Viral Vector Manufacturing Companies, Technological Advancements and Growth Analysis 2019 by Disease, Type, Application Global Market Forecast till 2023
Viral Vector Manufacturing Market Research Report: by Type (Retroviral Vectors, Adenoviral Vectors and others), by Disease (Genetic Disorders, Infectious Diseases, and others), by Application (Gene Therapy, Vaccinology), by End User — Global Forecast till 2023
viral vector manufacturing market is expected to grow significantly over the forecast period. It is projected that the global viral vector manufacturing market is expected to register a CAGR Approx. 22.65% with an expected market value of USD 319 million during the forecast period of 2018–2023.
Request free sample [email protected] https://www.marketresearchfuture.com/sample_request/6890
Gene therapy is one of the preferred treatment options for most chronic diseases, involving insertion of a functional copy of a gene into a defective cell. Viral vector methods are used in effective transfer of therapeutic gene into the target cells. Viral vectors used in gene therapy include retroviral vectors, adenoviral vectors and adeno-associated viral vectors.
Market Key Players
Some of the key players in the global viral vector manufacturing market are FinVector Vision Therapies, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., and Kaneka Eurogentec S.A.
The global viral vector manufacturing market has been segmented into type, disease, application, and end-user.
The market, on the basis of type, has been segmented retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors.
The market, by retroviral vectors, has been further segmented into lentiviral vectors and gamma-retroviral vectors.
The market, by disease, has been segmented into cancer, genetic disorders, infectious diseases, and others.
The market, by application, has been segmented into gene therapy and vaccinology.
The market, by end-user, has been segmented into pharmaceutical and biotechnology companies, research institutes, and others. The market, by pharmaceutical and biotechnology companies, is expected to hold the largest share in the market owing to the increasing demand for therapies, whereas the research institutes segment is projected to be the fastest growing segment due to growing awareness and specificity of viral vectors in treating the diseases.
- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Private Research institutes
- Diagnostic Laboratories
- Government Research Institutes
- Academic Institutes and Universities
Brows Complete Research [email protected] https://www.marketresearchfuture.com/reports/viral-vector-manufacturing-market-6890
The global viral vector manufacturing market is currently dominated by many market players. The major players in the market are engaged in new product launches and strategic collaborations to strengthen its market position. For instance, in April 2018, GE Healthcare, a subsidiary of General Electric Company, launched a ready-to-run factory-in-a-box to speed up the manufacturing of viral vector-based therapeutics, including viral vector-based vaccines, oncolytic viruses and gene and cell therapies.
The Americas is projected to dominate the global viral vector manufacturing market due to a well-developed healthcare sector and rising prevalence of autoimmune and chronic diseases. According to a study published by Partnership to Fight Chronic Disease (PFCD) in 2016, 191 million people in America had at least 1 chronic disease, whereas 75 million had 2 or more chronic diseases in the year 2015. Europe is expected to hold the second largest position in the global viral vector manufacturing market. The market growth in this region is attributed to the availability of funds for research and increasing healthcare expenditure. According to the European Commission, in 2016 the total expenditure of the governments of the European Union on health amounted to 7.1% of GDP. Also, according to National Institute of Health Funding (NIHR) in the year 2016, a funding of Euro 928 million was announced for new NIHR Biomedical Research Centres (BRC) and NIHR Clinical Research Facilities (CRF) for 5 years starting from April 2017.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies. On the other hand, the Middle East and Africa has the least share of the market.
Inquire for Discount and any Customization https://www.marketresearchfuture.com/enquiry/6890
MRFR leverages its in-house expertise for drawing insightful conclusions into the market. Extensive primary and secondary research are undertaken which include SEC filings, interviews with stakeholders across the value chain, whitepaper references, etc. for backing the research findings. Top-down and bottom-up approaches employed validate the authenticity of the statistical observations available in the report. Furthermore, a multi-layer verification process is applied for eliminating deviations and discrepancies.
About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Market Research Future
+1 646 845 9312